OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov) - Apr 9, 2025 - P2 | N=40 | Not yet recruiting | Sponsor: Seoul National University Hospital
New P2 trial • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology
|